Oropharyngeal Burkitt lymphoma masquerading as oropharyngeal carcinoma in an adult: A diagnostic challenge

sudeep kc^1 and Himani Poudyal²

April 05, 2024

Oropharyngeal Burkitt lymphoma masquerading as oropharyngeal carcinoma in an adult: A diagnostic challenge

Dr. Sudeep KC¹ | Dr. Himani Poudyal²

Department of Radiology, Patan Academy of Health Sciences. Lalitpur, Nepal

Department of Internal Medicine, Dhulikhel Hospital, Nepal

1 | INTRODUCTION

Burkitt lymphoma (BL) is a non-Hodgkin B-cell lymphoma derived from germinal center lymphoid B cells; named after Dennis Parsons Burkitt, an Irish surgeon who first described it as sarcoma of jaws in children from equatorial Africa in 1958. Burkitt lymphoma accounts for 1–5% of all non-Hodgkin lymphoma cases. It is uncommon in adults and usually involves the gastrointestinal system, central nervous system or the head-and-neck region. Sporadic Burkitt's lymphoma is relatively rare in the head and neck region, accounting for about 25% of all cases. Burkitt's lymphoma is the fastest-growing tumour in humans, with a cell-doubling time of about 24–48 hours. The etiology of this tumor is debatable, but strong evidence implicates Epstein-Barr virus in its development. Three distinct forms of Burkitt's lymphoma have been described; each of them having own clinical and epidemiological features. Multi-agent chemotherapy is the mainstay of Burkitt's lymphoma treatment.

This case report presents the diagnostic challenges encountered in identifying oropharyngeal Burkitt lymphoma (BL) in a 41- year-old male who initially presented with mass lesion in oropharynx. Owing to rarity of BL in the oropharynx, this case underscores the importance of considering rare malignancies in atypical presentations and highlights the role of comprehensive diagnostic approaches in clinical management.

2 | CASE PRESENTATION

41-year, male, smoker 15 pack year, occasional alcohol drinker, with no prior co-morbidities and notable previous medical history presented to the Otolaryngology Clinic with complaints of sore throat and something stuck in right side of throat for 2 months. He had no history of fever, night sweats, dysphagia, odynophagia and difficulty in breathing. On examination of the oral cavity, polypoidal pinkish-white colored tissue mass lesion was seen in right side of the oropharynx. Rest of the clinical examination were unremarkable.

2.1 METHODS

DIFFERENTIAL DIAGNOSIS:

On the basis of history and clinical examination, following differential diagnosis were considered.

¹Patan Academy of Health Sciences

²Dhulikhel Hospital

Oropharyngeal carcinoma

Lymphoma

INVESTIGATIONS:

Imaging Findings:

In suspicion of oro-pharyngeal malignancy, the patient underwent CE MRI of neck which showed a homogenously enhancing well circumscribed lobulated T1 hypointensity and T2 hyper intensity lesion measuring $4.0 \times 2.8 \times 2.0$ cm involving the right side of the oropharynx and tonsil(Fig 1). The lesion was causing partial effacement of the right side of vallecula, without midline extension of the lesion noted. No extension of the lesion beyond the confinement of oropharynx seen. Diffusion restriction noted with ADC value of $0.4 \times 10^{-3\text{mm}2/\text{sec}}$ on b value of 800. Patient was counselled about the possibility of malignant lesion and was advised for biopsy to rule out malignancy. Punch biopsy was done and histopathology followed by immunochemistry and Interphase fluorescence in situ hybridization (FISH) confirmed it as case of Burkitt Lymphoma.

Microscopic Findings showed multiple fragments of tissue, partially lined by non-keratinized stratified squamous epithelium. Sub epithelium showed infiltration by monotonous population of atypical lymphoid cells. Those atypical lymphoid cells were intermediate to large in size with round to ovoid with coarse chromatin, irregular nuclear membrane, scant cytoplasm. Cytoplasm was scant in amount. Immunohistochemistry showed atypical lymphoid cells which were diffusely positive for CD45, CD20, PAX-5, CD10, BCL6 (weak), MUM-1, c-MYC (45%), while they are negative for CK (AE1/AE3), CD3, BCL2, Cyclin-D1, CD21 and CD34. Ki67 proliferation index is approximately 90%.

Thoracic abdominal and pelvic CT scans did not show any distant extension of the disease. Bone marrow aspiration and biopsy showed normocellular marrow. The complete blood count was unremarkable. Human immunodeficiency virus (HIV) serology was negative. Serology testing was positive for anti-Epstein–Barr virus IgG.

Treatment, Outcome and Follow up:

He was stared on R-Da-EPOCH regimen(Rituximab, etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin). CT scan following the 6th cycle showed a complete regression of lesion(figure 2)

DISCUSSION

Lymphoid neoplasm encompasses group of white cell neoplasm varying in clinical presentation and behavior; Leukemias arising in bone marrow and circulating peripheral blood, lymphomas appearing as tumour masses from lymph nodes or other organs and plasma cell dyscrasias composed predominantly of plasma cells. Sometimes, distinction between these clinical categories of lymphoid neoplasia is difficult.⁶

Lymphomas are divided into two major group; Hodgkin and Non-Hodgkin lymphoma. The non-Hodgkin lymphomas are further sub-divided into B-cell and T-cell lymphomas. Burkitt's Lymphoma belongs to peripheral B cell neoplasm. There are 3 different types of BL: endemic (African) form, the sporadic (non-African) form and immunodeficiency-linked variety. The endemic form, which is the most prevalent worldwide; affects younger children (4 to 7 years) involving the head and neck (maxilla and mandible involvement in 58%). Concomitant (endemic) malaria (or other infections) impairs immune competence; allowing sustained B cell proliferation commonly seen in this variant. Symptoms include cervical lymphadenopathy, swelling of the jaw or facial mass, proptosis, teeth mobility, paresthesia, and pain. Sporadic Burkitt's lymphoma (usually seen in European populations) shows gastrointestinal involvement (56% of the cases) and is found more often in older children(male> female). Both endemic and Sporadic Burkitt's lymphoma rarely arises in the lymph nodes. Immunodeficiency associated Burkitt lymphoma is frequently seen in AIDS patients and patients on immunosuppressive drugs following organ transplantation and can be found in extra-nodal sites; abdomen

being common site. Abdominal pain, vomiting, bowel obstruction and gastrointestinal bleeding constitutes the usual clinical presentation. 10

Manifestations of BL are variable depending on the site of involvement and the extension toward the adjacent structures. Sometimes, systemic symptoms such as fever, weight loss, and headache might be seen. ¹¹ Rapid progression of symptoms can be seen that can even reach 24 to 48 hours. ⁹ Our patient mainly presented with sore throat and foreign body sensation in the throat that was attributed to the oropharyngeal extension. In fact, symptoms in oropharyngeal BL are not specific to this entity and can delay the diagnosis, since BL mainly manifests with cervical lymphadenopathy. Physical examination findings can also be misleading as oropharyngeal BL typically presents as a polypoid mass resembling other tumorous condition. ⁹

Although the diagnosis of BL is confirmed pathologically, multimodality imaging approach imaging plays a critical role throughout the clinical course from diagnosis to follow up imaging. ¹²According to the National Comprehensive Cancer Network (NCCN) guidelines, initial staging should be performed with cervical and abdominal ultrasound, CT of the chest, abdomen, and pelvis. Depending on the clinical presentation, contrast-enhanced neck and/or brain MRI may also be done. ¹² CT scan is a crucial to assess tumor localization, staging of the disease and post-treatment monitoring. Currently, Gadolinium enhanced MRI is also the best imaging modality for confirming oropharyngeal location, extension, its relationship to the adjacent structures, and follow-up of BL. Compared with CT, MR imaging can demonstrate homogenously enhancing mass with isointense signal on T1-weighted images and an iso or hyper-intense signal on T2-weighted images due to the cellularity and tends to infiltrate surrounding structures without their destruction, especially in sporadic forms. In contrast, endemic variants are characterized by osteolytic bone lesion with destruction of maxilla-facial bones with an enlargement and invasion of the adjacent structures. ¹³ Our patient also presented as an infiltrating homogenous mass with a hypo-intense signal on T2-weighted images. However, CT and MRI findings are not specific to this entity, and their findings can mimic other aggressive diseases of the oropharynx.

Role of diffusion weighted imaging (DWI) and ADC value in BL is still under study. Positron emission tomography (PET), when combined with CT, offers the advantage of combining functional information with anatomic imaging. ¹⁴An increasing amount of research is being done to assess the value of PET/CT in patients with BL and should be performed if possible, provided it will not delay treatment. ¹²

Biopsy, immunohistochemistry and genetic analysis are other tests helpful to get correct diagnosis. All variants of Burkitt lymphoma share the same morphology and it is almost impossible to differentiate these three variants on microscopic features alone. They are strongly associated with translocations involving the MYC oncogene on chromosome 8. Histopathology, BL typically has characteristic starry-sky pattern. However, immunohistochemistry is a useful method for identifying particular tumor cells that includes expression of CD20, CD10, and bcl-6, Ki-67 proliferation rate.¹⁵

Bone marrow, Cerebrospinal fluid, Lactate Dehydrogenase Level, HIV and Epstein-Barr Virus serology may also be required. 16 EBV exhibits strong tropism for B cells and infects them, causing them to proliferate. In our case, the patient had positive antibodies for Epstein-Barr virus. Virtually all cases of endemic BL carry EBV genome whereas < 30% of sporadic and immunosuppression-associated variant are associated with this EBV virus. 17

The definitive treatment of BL is often based on the patient's age and the location of tumor. Different modalities such as surgery, radiotherapy, chemotherapy, and radioimmunotherapy have been used to treat Burkitt's lymphoma, but systemic chemotherapy is mainstay of treatment. BL dramatically responds to chemotherapies that includes cyclophosphamide, vincristine, methotrexate, and prednisone causing regressions of tumor and often lead to long-term remission.¹⁸ Our patient was also placed under complex chemotherapy resulting in the regression of the mass confirmed on post-therapeutic imaging.

The role of surgery in BL is still controversial. Surgical treatment is generally not required unless disease complications require prompt surgical intervention such as in cases of bowel obstruction, optic nerve decompression and airway obstruction. ¹⁹

Prognosis depends on the stage of the disease at presentation, age of patient, chemotherapy, lactate dehydrogenase levels and the association with HIV. Patients who receive an early treatment are associated with better outcomes in comparison to the delayed treatment which can cause BL to reach other distant organs. ²⁰ Patients with relapsed disease usually present symptomatically and within the first year after the completion of treatment. Relapsed disease may occur at the sites of original presentation or remotely. ¹²

CONCLUSION

BL has a very heterogeneous pattern of presentation and clinical course. The diagnosis can be suspected on CT and MRI, but the confirmation requires histopathology and immunohistochemistry. Burkitt lymphoma is high grade tumour however, with aggressive chemotherapy regimens, majority of the patient can be cured. Delays in diagnosis and treatment have a significant impact on prognosis. In addition, radiologists need to identify typical and uncommon sites and presentations in order to properly guide clinicians considering the urgency of possible therapy.

AUTHOR CONTRIBUTIONS

Sudeep KC: Conceptualization; Writing – original draft; writing – review and editing.

Himani Poudyal: Writing - original draft; writing - review and editing.

orcid ID: Sudeep KC 0000-0002-2826-4855

ACKNOWLEDGEMENTS

Author would like to thanks to patient who participated in this case report and collaborative efforts of ENT and hemato-oncology teams.

FUNDING: No funding sources.

DATA AVAILABILITY STATEMENT: The data that support the findings of this study are available on request from the corresponding author

CONFLICT OF INTEREST: The authors declare that there is no conflict-of-interest regarding the publication of this paper.

ETHICS STATEMENT: Need for ethics approval waived. Consent from the patient deemed to be enough.

CONSENT: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent will be available for review by the editor-inchief of this journal if requested

References:

- 1. Magrath L. Denis Burkitt and the African lymphoma. ecancermedicalscience [Internet]. 2010 [cited 2024 Feb 7]; Available from: http://ecancer.org/ecms/3/159. DOI | PubMed | Full Text |
- 2. Al Burshaid D, Nasser M, Nagaraj V, Al Shehabi M. Sporadic Burkitt's lymphoma of the hypopharynx: A case report. Saudi J Med Med Sci. 2019;7(2):114. DOI | PubMed | Full Text |
- 3. Lee DH, Yu MS, Lee BJ. Primary Burkitt's Lymphoma in the Nasal Cavity and Paranasal Sinuses. Clin Exp Otorhinolaryngol. 2013;6(3):184. DOI | PubMed | Full Text |
- 4. Delecluse HJ, Feederle R, O'Sullivan B, Taniere P. Epstein Barr virus-associated tumours: an update for the attention of the working pathologist. J Clin Pathol. 2006 Dec 20;60(12):1358–64. DOI | PubMed | Full Text |
- 5. God JM, Haque A. Burkitt Lymphoma: Pathogenesis and Immune Evasion. J Oncol. 2010; 2010:1–14. DOI | PubMed | Full Text |
- 6. Baba AI, Câtoi C. Comparative Oncology. Bucharest (RO): The Publishing House of the Romanian Academy; 2007. Chapter 17, TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUES. Available from: https://www.ncbi.nlm.nih.gov/books/NBK9562. In.

- 7. Bispo JAB, Pinheiro PS, Kobetz EK. Epidemiology and Etiology of Leukemia and Lymphoma. Cold Spring Harb Perspect Med. 2020 Jun;10(6):a 034819. DOI | PubMed | Full Text|
- 8. Patankar S. Burkitt's lymphoma of maxillary gingiva: A case report. World J Clin Cases. 2015;3(12):1011. DOI | PubMed | Full Text |
- 9. Kallel S, Ayedi S, Ben Ayed M, Salem N, Achour I, Ben Mahfoudh K, et al. Sinonasal Burkitt Lymphoma in a 2-Year-Old Child: An Uncommon Case Report. Ear Nose Throat J. 2023 Jun 26;01455613231182659. DOI | Full Text |
- 10. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci. 2007 Sep;7(3):166–75. DOI | PubMed| Full Text |
- 11. Storck K, Brandstetter M, Keller U, Knopf A. Clinical presentation and characteristics of lymphoma in the head and neck region. Head Face Med. 2019 Dec;15(1):1. DOI | PubMed | Full Text |
- 12. Kalisz K, Alessandrino F, Beck R, Smith D, Kikano E, Ramaiya NH, et al. An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging. 2019 Dec;10(1):56. DOI | PubMed | Full Text |
- 13. Derinkuyu BE, Boyunaga O, Oztunali C, Tekkesin F, Damar C, Alimli AG, et al. Imaging features of Burkitt lymphoma in pediatric patients. Diagn Interv Radiol. 2015 Dec 29;22(1):95–100. DOI | PubMed | Full Text |
- 14. Giraudo C, Simeone R, Fosio M, Marino D, Cecchin D. Diagnostic Value of PET/MR with DWI for Burkitt Lymphoma. Diagnostics. 2021 Oct 11;11(10):1867. DOI | PubMed | Full Text |
- 15. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006 Jan;19(1):25–33. DOI | PubMed| Full Text |
- 16. Graham BS, Lynch DT. Burkitt Lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Feb 7]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK538148.
- 17. Rowe M, Fitzsimmons L, Bell AI. Epstein-Barr virus and Burkitt lymphoma. Chin J Cancer [Internet]. 2014 Nov 21 [cited 2024 Feb 7]; Available from: http://www.cjcsysu.cn/abstract_-AOP.asp?fr=doi&id=14-190. DOI | PubMed | Full Text |
- 18. Magrath I. Towards Curative Therapy in Burkitt Lymphoma: The Role of Early African Studies in Demonstrating the Value of Combination Therapy and CNS Prophylaxis. Adv Hematol. 2012; 2012:1–7. DOI | PubMed | Full Text |
- 19. Gahukamble DB, Khamage AS. Limitations of surgery in intraabdominal Burkitt's lymphoma in children. J Pediatr Surg. 1995 Apr;30(4):519–22. DOI | PubMed| Full Text |
- 20. Cunha KCCMS, Oliveira MCLA, Gomes ACS, Castro LPFD, Viana MB. Clinical course and prognostic factors of children with Burkitt's lymphoma in a developing country: the experience of a single centre in Brazil. Rev Bras Hematol E Hemoter. 2012;34(5):361–6. DOI | PubMed | Full Text |



